287 related articles for article (PubMed ID: 34375015)
1. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
2. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
3. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
4. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
5. States as Activists.
Buck ID
J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
[TBL] [Abstract][Full Text] [Related]
6. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
8. California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.
Gudiksen KL; Brown TT; Whaley CM; King JS
Health Aff (Millwood); 2018 Sep; 37(9):1503-1508. PubMed ID: 30179546
[TBL] [Abstract][Full Text] [Related]
9. Value-Based Pricing and State Reform of Prescription Drug Costs.
Hwang TJ; Kesselheim AS; Sarpatwari A
JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
[No Abstract] [Full Text] [Related]
10. State strategies to address medicaid prescription spending: negotiated pricing vs price transparency.
Noh S; Janousek CL; Park JH
Health Econ Policy Law; 2021 Apr; 16(2):201-215. PubMed ID: 32349843
[TBL] [Abstract][Full Text] [Related]
11. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
12. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
Bachhuber MA
Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
[TBL] [Abstract][Full Text] [Related]
13. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
Seay M; Varma P
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
[TBL] [Abstract][Full Text] [Related]
15. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
16. How Medicare could get better prices on prescription drugs.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
[TBL] [Abstract][Full Text] [Related]
17. Physician and Patient Adjustment to Reference Pricing for Drugs.
Robinson JC; Whaley C; Brown TT; Dhruva SS
JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
19. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
